INFLIXIMAB PROTOCOL FOR PAEDIATRIC RHEUMATOLOGY
|
|
- Amber West
- 5 years ago
- Views:
Transcription
1 INFLIXIMAB PROTOCOL FOR PAEDIATRIC RHEUMATOLOGY 1. Background and indications Infliximab is a drug that blocks a key protein of all inflammatory processes called Tumour Necrosis Factor (or TNF). TNF is a signalling protein that increases the activity of cells involved in inflammation and in patients with arthritis its concentration is particularly high. It has been shown in arthritis patients that persistently high levels contribute to tissue damage. Infliximab stops TNF from binding to cells, thereby reducing inflammation. Infliximab should only be used in patients who do not respond to other treatments. Patients receiving infliximab should continue to receive methotrexate or a similar type of drug. Infliximab is not currently licensed for use in JIA or uveitis. Infliximab is NICE approved for children aged 6-17 years with severe Inflammatory Bowel disease (Crohn s and ulcerative colitis) and in adults with severe psoriasis, psoriatic arthritis, Rheumatoid arthritis and Inflammatory Bowel Disease (Crohn's and Ulcerative colitis). However it is widely used for the treatment of severe juvenile arthritis and/or refractory uveitis and in select cases of refractory Juvenile Dermatomyositis and other rare autoimmune/autoinflammatory conditions, by physicians in the UK and worldwide, with a reasonably good efficacy/ safety profile. If specific details needed, please contact the Paediatric Rheumatology team for latest evidence on this. 2. Dose and frequency The dose for infliximab given for JIA or uveitis is 6mg/kg but can go up to 10mg/kg Induction involves three doses at weeks 0, 2, and 6 For maintenance, most patients will then receive infliximab every 4-6 weeks 3. Procedures 3.1. Consent Written informed consent should be taken by a clinician at SpR or Consultant grades or equivalent, and should be filed in the medical notes. If taken at NOC, this will be scanned and filed on EPR records Pre-treatment tests Prior to the first infusion, all patients should have had the following (unless reason for deviation recorded by Consultant in the medical notes): TB Elispot (within the last 6 months or sooner if recent travel to a TB-endemic area) +/- CXR HIV, HBV, and HCV serologies if high risk The dates of these tests should be completed on the biologics checklist (scanned and filed in EPR records)
2 3.3. Cannulation and bloods on the day Cannulation is usually undertaken by one of the day ward ANPs. If they are not available it should be undertaken by a member of the medical team. Routine bloods should be sent (FBC, ESR, U&Es, LFTs, CRP) No need to wait for results prior to infusion unless abnormal results from previous admission Clerking Clinicians or specialist nurses trained in clerking for infliximab infusions should complete the biologics clerking form and ensure that patients are documented fit for infliximab prior to administration In the following circumstances please discuss with one of the paediatric rheumatology team as it may be necessary to withhold the infliximab. Latest blood results show: o Low blood cell count (Hb <100, platelets <150) or symptoms and signs which may include bruising, bleeding, pallor o Neutrophils < 1.5 cells x 10 9 / l o Liver Function - ALT >120 If patient has a temperature of 38 C or above. Evidence of an infection or contact with an infectious disease. The infection could be an open cut or sore, a chest infection or an infection that affects the whole body (such as the flu or chicken pox). The patient has heart failure or other heart conditions, multiple sclerosis, or Guillain- Barré syndrome, or if the patient has experienced numbness, tingling, or had a seizure. Lived in or visited an area of the country where an infection called histoplasmosis or coccidioidomycosis (an infection caused by a fungus that affects the lungs) is common. The patient has recently received any live vaccinations: o Live vaccines such as oral polio, rubella, MMR, chicken pox, BCG and yellow fever should not be given whilst patient is on infliximab. o Annual flu vaccines (IM only) are safe, recommended and should be given annually.
3 Infliximab SHOULD NOT BE GIVEN if the patient: Has had a severe allergic reaction to Infliximab or any other product that was made with murine (mouse) proteins. Has had TB (tuberculosis), unless suitable antibiotics are being given to treat TB, or if there has been recent contact with someone who might have TB. A CXR (+/- mantoux/elispot if considered high risk) must have been performed in all patients Pre-medication Prescribe IV Hydrocortisone 4 mg/kg (maximum 200mg) to be administered prior to infusion. Antihistamines should not be routinely prescribed. 3.6 Drug preparation Store in a refrigerator (2 C - 8 C). Infliximab is available in 100 mg vials Reconstitute each 100 mg vial with 10 ml water for injections. Insert the syringe needle into the vial through the centre of the rubber stopper and direct the stream of water for injections to the glass wall of the vial. Do not use the vial if the vacuum is not present. Gently swirl or slowly roll the vial until completely dissolved. Do not shake. Foaming may occur (normal). Allow the reconstituted solution to stand for 5 minutes. Solution should be yellow, opalescent and not cloudy. Calculate dose of infliximab and fluid volume to be withdrawn Dilute required dose to 250 ml in 0.9% saline Infliximab must be administered using a giving set with a low protein binding filter of 1.2 microns or less. The IV line must not be used for any other medications or fluids Administration rate and monitoring Impact of gradual increase in infusion rate on infusion reaction incidence has never been validated in controlled studies. Data on beneficial effect of corticosteroid co-administration are limited, and antihistamines may paradoxically increase the rate of infusion reaction. Meta-analysis showed no impact of impact of rapid infusion on incidence of infusion reactions across 10 studies comprising >8000 infusions for a variety of indications. There are limited data on safety of 1-hour protocols in PIBD, although in fact the practice may be quite common. Adult patients at the JR and NOC who are established on infliximab routinely receive infusions over minutes. In deciding on administration duration, consult the following decision tree, the objective of which is to facilitate provision of 1-hour infusion to children established on treatment with infliximab, who have tolerated at least 4 doses, and have not had treatment interruption or infliximab hypersensitivity. [adapted from gastro protocol]
4 Administration Schedule A: Infusate: prescribed dose of infliximab made up to 250 ml with 0.9% saline Infuse at: 20ml/h for 15 minutes, then 60ml/h for 30 minutes, then 80ml/h for 30 minutes, then 150 ml/h for the remainder of the infusion Monitor observations every 30 minutes during the infusion. Monitor observations every 30 minutes for 120 minutes (2 hours) after completion of the infusion. Administration Schedule B: Infusate: prescribed dose of infliximab made up to 250 ml with 0.9% saline Infuse at: 100 ml/h for 15 minutes, then 300 ml/h for the remainder of the infusion Monitor observations every 30 minutes during the infusion and for 60 minutes after the infusion. If there is a history of infusion related reactions: In the presence of medical staff give an intravenous test dose of 3ml filtered medication over 15minutes. If a reaction occurs stop infusion and treat If no reaction occurs, continue as recommended infusion schedule.
5 4. Side effects and infusion reactions Possible side effects during the infusion Most patients do not experience side effects, but possible infusion related reactions include headache, fever, facial flushing, pruritus, myalgia, nausea, chest tightness, dyspnoea, vomiting, erythema, abdominal discomfort, shivers, hypertension, light headedness, hypotension and palpitations. For many patients these reactions resolve with slowing the infusion rate. From previous studies it has been shown that infusion reactions experienced were generally mild to moderate and they decreased in frequency with repeated dosing. Some patients have had allergic reactions 3 to 12 days after receiving Infliximab. The symptoms of this type of delayed reaction may include fever, rash, headache, and muscle or joint pain. If these symptoms or any other unusual symptoms occur the paediatric rheumatology team should be informed as well as the GP. Infusion reactions Infliximab has been associated with immediate infusion reactions. These may result from classical IgE-mediated allergy, or from immune-driven release of vasoactive mediators ( cytokine storm ). Reactions can be graded as mild, moderate or severe: Mild: pruritus; flushing; myalgia; low-grade fever Moderate: chest tightness; urticaria; hypertension; high-grade fever Severe: bronchospasm; angioedema; hypotension Management depends on severity of the reaction and is summarised in the decision tree below. If in doubt, prioritise safety at all times: stop the infusion and call for help.
6 Management of Infliximab infusion reactions in paediatric rheumatology
7 Contacts for Paediatric Rheumatology Team 1. Paediatric Rheumatology Nurse Specialists (7) Paediatric Rheumatology consultant on-call via switchboard 3. Out of hours contact can be made with the on-call Paediatric Rheumatology consultant via switchboard References SPC for Infliximab found at Ruperto, N et al (2007) A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis; Arthritis and Rheumatism Kendall,E, Inness, E, Parsons, E, Wilkinson, N (2012) Audit of Blood Monitoring for Patients receiving Biologic Therapies. Oxford Paediatric and Adolescent Rheumatology Centre. Nuffield Orthopaedic Centre. Oxford University Hospitals NHS Foundation Trust (2016) Infliximab monograph Modified from the Paediatric Gastroenterology Infliximab Protocol. Oxford Children s Hospital. OUH Trust.
Rituximab (MabThera) PROTOCOL FOR PAEDIATRIC RHEUMATOLOGY UNIT.
Rituximab (MabThera) PROTOCOL FOR PAEDIATRIC RHEUMATOLOGY UNIT. Rituximab is a monoclonal antibody that works by removing B-cells (a type of white blood cell that produce antibodies). The aim of the B
More informationMedication Guide Enbrel (en-brel) (etanercept)
Medication Guide Enbrel (en-brel) (etanercept) Read the Medication Guide that comes with Enbrel before you start using it and each time you get a refill. There may be new information. This Medication Guide
More informationINFLECTRA Infliximab Infusion 1,2 & 3
DEPARTMENT OF RHEUMATOLOGY DAY CASE ADMISSION RECORD PATIENT DAY CASE BOOKING REQUEST To be completed by Consultant, Registrar requesting day case Admission Hospital No. Surname Forename Address INFLECTRA
More informationWe will review the need for continuing treatment with you after 3 months and again after one year.
Patient Information Drugs for Inflammatory Bowel Disease Adalimumab (Humira) Clinical Nurse Specialist - Allyson Lewis Clinical Nurse Specialist Gareth Lloyd-Ford Clinical Nurse Specialist Lynsey Hook
More informationWhy have I been selected for treatment with adalimumab?
ADALIMUMAB What are the aims of this leaflet? This leaflet has been written to help you understand more about adalimumab (Humira TM ). It tells you what it is, how it works, how it is used to treat skin
More informationAnti-Tumor Necrosis Factor (Anti-TNF)
Anti-Tumor Necrosis Factor (Anti-TNF) 110465 Anti-TNF.indd 1 9/20/16 9:01 AM s About your medicine Anti-tumor necrosis factor (anti-tnf) is a type of medicine called biologic agent that targets substance
More informationMEDICATION GUIDE HUMIRA
MEDICATION GUIDE HUMIRA (Hu-MARE-ah) (adalimumab) injection Read the Medication Guide that comes with HUMIRA before you start taking it and each time you get a refill. There may be new information. This
More informationREMICADE Infliximab Consumer Medicine Information
REMICADE Infliximab Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about It does not contain all the available information. It does not take the place
More informationMethotrexate for inflammatory bowel disease: what you need to know
Methotrexate for inflammatory bowel disease: what you need to know This leaflet aims to answer your questions about taking methotrexate for inflammatory bowel disease (IBD). If you have any questions or
More informationSUMMARY OF SHARED CARE PROTOCOL FOR MYCOPHENOLATE MOFETIL (MMF)
SUMMARY OF SHARED CARE PROTOCOL FOR MYCOPHENOLATE MOFETIL (MMF) Please refer to Chester Rheumatology shared care protocol for MMF and separate responsibilities document for full details. Responsibilities
More informationJUST FOR KIDS SELECTED IMPORTANT SAFETY INFORMATION
JUST FOR KIDS For children ages 6-17 with moderately to severely active Crohn s disease or ulcerative colitis (UC) who haven t responded well to other therapies SELECTED IMPORTANT SAFETY INFORMATION REMICADE
More informationIf your IBD has not been well controlled, or is flaring up quite often, methotrexate may be added to your treatment.
Patient Information Drugs for Inflammatory Bowel Disease Methotrexate Clinical Nurse Specialist - Allyson Lewis Clinical Nurse Specialist Gareth Lloyd-Ford Nurse Specialist Lynsey Hook If your IBD has
More informationShow your doctor how juvenile idiopathic arthritis affects your child
Date: Physician: Show your doctor how juvenile idiopathic arthritis affects your child Moderate to severe polyarticular juvenile idiopathic arthritis (JIA) comes with some common symptoms like joint pain,
More informationInfliximab for Inflammatory Bowel Disease. An information guide
TO PROVIDE THE VERY BEST CARE FOR EACH PATIENT ON EVERY OCCASION Infliximab for Inflammatory Bowel Disease An information guide Infliximab for Inflammatory Bowel Disease Infliximab is a type of drug known
More informationStep-by-step instructions for intravenous (iv) infusions for patients with:
Step-by-step instructions for intravenous (iv) infusions for patients with: Rheumatoid Arthritis (RA) Systemic Juvenile Idiopathic Arthritis (sjia) Polyarticular Juvenile Idiopathic Arthritis (pjia) Please
More informationMethotrexate in Inflammatory Bowel Disease. An information guide
TO PROVIDE THE VERY BEST CARE FOR EACH PATIENT ON EVERY OCCASION Methotrexate in Inflammatory Bowel Disease An information guide Methotrexate in Inflammatory Bowel Disease Your doctor is planning to start
More informationAdalimumab for Inflammatory Bowel Disease. An information guide
TO PROVIDE THE VERY BEST CARE FOR EACH PATIENT ON EVERY OCCASION Adalimumab for Inflammatory Bowel Disease An information guide Adalimumab for Inflammatory Bowel Disease (IBD) What is Adalimumab and how
More informationJoint Trust Guideline for the Management of Methylprednisolone Sodium Succinate Infusion for Child or Young Person A Clinical Guideline
A Clinical Guideline For Use in: Children s Department By: Registered Paediatric Nurses and Medical Staff Children with active inflammatory bowel disease, For: active rheumatological conditions or other
More informationShared Care Guideline
Shared Care Guideline Mercaptopurine inflammatory bowel disease Executive Summary Unlicensed indication, but widely established use of mercaptopurine. Dosing: 25mg daily for two weeks, then 1-1.5mg/kg
More informationSHARED CARE PRESCRIBING GUIDELINE LEFLUNOMIDE IN ADULT PATIENTS WITH RHEUMATOID ARTHRITIS DOCUMENT DETAILS
SHARED CARE PRESCRIBING GUIDELINE LEFLUNOMIDE IN ADULT PATIENTS WITH RHEUMATOID ARTHRITIS DOCUMENT DETAILS Document type Shared Care Prescribing Guideline Document name Shared Care Prescribing Guideline:
More informationINFUSING. ORENCIA (abatacept) IV INDICATION/USAGE. Your go-to guide for preparing and administering an ORENCIA intravenous (IV) infusion
INFUSING ORENCIA (abatacept) IV Your go-to guide for preparing and administering an ORENCIA intravenous (IV) infusion INDICATION/USAGE Adult Rheumatoid Arthritis (RA): ORENCIA is indicated for reducing
More informationInfliximab Drug information. Infliximab can treat rheumatoid arthritis and psoriatic arthritis.
Infliximab Drug information Infliximab can treat rheumatoid arthritis and psoriatic arthritis. Infliximab should effectively treat your condition, and stop it causing damage to your joints. It has been
More informationPART III: CONSUMER INFORMATION
PART III: CONSUMER INFORMATION Pr INFLECTRA (infliximab for Injection) INFLECTRA is a subsequent entry biologic (SEB) to REMICADE. An SEB is a biologic drug product that is authorized based on its likeness
More informationInformation about... Infliximab. Ophthalmology Service Scottish Uveitis National Managed Clinical Network
Information about... Infliximab Ophthalmology Service Scottish Uveitis National Managed Clinical Network What is infliximab? Infliximab is a drug used in the treatment of inflammatory conditions including
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION PR RENFLEXIS TM (pronounced) (Infliximab for Injection) Powder for Solution, Sterile, Lyophilized, 100
More informationSIMPONI Golimumab (rmc) Consumer Medicine Information
SIMPONI Golimumab (rmc) Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about SIMPONI. It does not contain all the available information. It does not take
More informationTocilizumab (Actemra )
Tocilizumab (Actemra ) How does it works? Actemra is a biologic medicine that helps keep the immune system from attacking healthy tissues in the body by blocking the protein IL-6 (interleukin-6). Actemra
More informationSirolimus 1mg/1ml oral solution
Great Ormond Street Hospital for Children NHS Foundation Trust: Information for Families Sirolimus 1mg/1ml oral solution You should read this information sheet in conjunction with any patient information
More informationLEFLUNOMIDE FOR USE IN RHEUMATOLOGY & PAEDIATRIC RHEUMATOLOGY Shared Care Protocol
Oxfordshire Clinical Commissioning Group LEFLUNOMIDE FOR USE IN RHEUMATOLOGY & PAEDIATRIC RHEUMATOLOGY Shared Care Protocol This protocol provides prescribing and monitoring guidance for leflunomide therapy.
More informationMethotrexate Methotrexate.indd 1 9/1/16 11:40 AM
Methotrexate 110465 Methotrexate.indd 1 9/1/16 11:40 AM This leaflet only provides information for patients being treated with methotrexate (25mg or less per week). About your medicine Methotrexate is
More informationPrescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationPrescribing Framework for Methotrexate for Immunosuppression in ADULTS
Hull & East Riding Prescribing Committee Prescribing Framework for Methotrexate for Immunosuppression in ADULTS Patient s Name:.. NHS Number: Patient s Address:... (Use addressograph sticker) GP s Name:...
More informationInflectra infliximab-dyyb. INFLECTRA (infliximab-dyyb) for injection available in the US 1
First FDA-approved mab biosimilar 1 INFLECTRA (infliximab-dyyb) for injection available in the US 1 INFLECTRA is biosimilar* to and has the same recommended dosage as Remicade (infliximab) 2 * Biosimilar
More informationo Your healthcare provider should test you for TB before starting CIMZIA.
Medication Guide CIMZIA (CIM-zee-uh) (certolizumab pegol) lyophilized powder or solution for subcutaneous use Read the Medication Guide that comes with CIMZIA before you start using it, and before each
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Drug: Methotrexate Introduction Indication: Licensed: Rheumatoid arthritis, severe psoriasis, severe active juvenile idiopathic arthritis, severe psoriatic arthritis, mild to moderate
More informationName of Shared Care Agreement: AZATHIOPRINE/6-MERCAPTOPURINE: Oral immunomodulating drugs for inflammatory bowel disease. Reference number: 01/2008
Name of Shared Care Agreement: AZATHIOPRINE/6-MERCAPTOPURINE: Oral immunomodulating drugs for inflammatory bowel disease. Reference number: 01/2008 Shared care agreement has been developed appropriately
More informationWhat prescribers need to know
HUMIRA Citrate-free presentations in an Electronic Medical Record (EMR) What prescribers need to know 2 / This is your guide to identifying HUMIRA Citrate-free presentations in your Electronic Medical
More informationSULFASALAZINE (Adults)
Shared Care Guideline DRUG: Introduction: SULFASALAZINE (Adults) Indication: Disease modifying drug for rheumatoid arthritis, psoriatic arthritis, undifferentiated arthritis, spondyloarthropathies, Crohn
More informationNHS Suffolk Shared Care Guidelines for the Treatment of Rheumatoid Arthritis with LEFLUNOMIDE
Suffolk Drug & Therapeutics Committee NHS Suffolk Shared Care Guidelines for the Treatment of Rheumatoid Arthritis with LEFLUNOMIDE What is a shared care document? Suffolk D&T operates a traffic light
More informationDERBY-BURTON LOCAL CANCER NETWORK FILENAME Peruse.DOC CONTROLLED DOC NO: CCPG R29
Pertuzumab + Trastuzumab + Docetaxel (Peruse study) A Multicenter, open-label, single arm study of Pertuzumab in combination with Trastuzumab and a Taxane in first-line treatment of patients with HER2-positive
More informationPART III: CONSUMER INFORMATION
PART III: CONSUMER INFORMATION Pr INFLECTRA (infliximab for Injection) INFLECTRA is a subsequent entry biologic (SEB) to REMICADE. An SEB is a biologic drug product that is authorized based on its likeness
More informationUse of abatacept in rheumatoid arthritis - patient information
Practical management of patients receiving abatacept 1 Use of abatacept in rheumatoid arthritis - patient information Evidence-based Medicine Official Recommendations Expert opinion Key points 1. Abatacept
More informationSHARED CARE PRESCRIBING GUIDELINE AZATHIOPRINE IN ADULT PATIENTS WITH RHEUMATOID ARTHRITIS DOCUMENT DETAILS
SHARED CARE PRESCRIBING GUIDELINE AZATHIOPRINE IN ADULT PATIENTS WITH RHEUMATOID ARTHRITIS DOCUMENT DETAILS Document type Shared Care Prescribing Guideline Document name Shared Care Prescribing Guideline:
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 October 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 3 October 2012 REMICADE 100 mg, powder for concentrate for solution for infusion B/1 vial (CIP code: 562 070-1) Applicant:
More informationSHARED CARE AGREEMENT: METHOTREXATE S/C
NB: This document should be read in conjunction with the current Summary of Product Characteristics (SPC) and BSR Guideline for disease-modifying anti-rheumatic drug (DMARD) therapy (available at www.rheumatology.org.uk/resources/guidelines/bsr_guidelines.aspx
More informationMEDICATION GUIDE. (tocilizumab)
MEDICATION GUIDE ACTEMRA (AC-TEM-RA) (tocilizumab) Read this Medication Guide before you start ACTEMRA and before each infusion. There may be new information. This Medication Guide does not take the place
More informationAzathioprine Shared Care Guideline for GPs
Indication: Azathioprine Shared Care Guideline for GPs Active rheumatoid arthritis and other types of inflammatory arthritis, systemic lupus erythematosus, dermatomyositis and polymyositis, vasculitis
More informationTreating inflammatory bowel disease
Treating inflammatory bowel disease Anti TNFa (Infliximab, Adalimumab and Golimumab) Information for patients Gastroenterology This leaflet should not replace the information provided by the drug manufacturer.
More informationRituximab (Rituxan )
Rituximab (Rituxan ) How does it work? Rituximab is a biologic medicine that helps keep the immune system from attacking healthy tissues in the body. Rituximab is used to treat the person with moderate
More informationTrust Protocol for the Management of Infliximab Infusions in Adult Patients with Rheumatological Conditions A Clinical Guideline recommended for use
Trust Protocol for the Management of Infliximab Infusions in Adult Patients with Rheumatological Conditions A Clinical Guideline recommended for use For use in: Rheumatology Day Unit By: Registered Nurses
More informationTocilizumab Tocilizumab
Drug information Tocilizumab Tocilizumab This leaflet provides information on tocilizumab and will answer any questions you have about the treatment. Arthritis Research UK produce and print our booklets
More informationHIGHLIGHTS OF PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use North American Coral Snake Antivenin (Equine) safely and effectively. See full prescribing information
More informationMabThera. SC. The wait is over. MabThera delivered in just 5 minutes. SC= subcutaneous injection
MabThera SC. The wait is over. MabThera delivered in just 5 minutes Abbreviated Prescribing Information MabThera 1400 mg solution for subcutaneous (SC) injection (Rituximab) Indications: Indicated in adults
More informationTrust Guideline. for Ciclosporin Treatment & Monitoring for Adult* Patients with Acute, Severe Ulcerative Colitis. (*ie aged 16 years and over)
Trust Guideline for Ciclosporin Treatment & Monitoring for Adult* Patients with Acute, Severe Ulcerative Colitis (*ie aged 16 years and over) abc A guideline recommended for use In: Gastroenterology/Medical
More informationHorizon Scanning Technology Summary. Abatacept (Orencia) for juvenile idiopathic arthritis. National Horizon Scanning Centre.
Horizon Scanning Technology Summary National Horizon Scanning Centre Abatacept (Orencia) for juvenile idiopathic arthritis June 2007 This technology summary is based on information available at the time
More informationPrescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationInfliximab infusion for patients with Crohn s disease. GI Unit Patient Information Leaflet
Infliximab infusion for patients with Crohn s disease GI Unit Patient Information Leaflet What is Infliximab? Infliximab (Remicade) is a medication that is used for patients with Crohn s disease whose
More informationSpecialty Pharmacies: What they are. Why they are different.
Specialty Pharmacies: What they are. Why they are different. A changing environment of medicines and pharmacies. Filling a prescription used to be as simple as going to the corner drug store. Today, the
More informationPackage leaflet: Information for the patient. Entyvio 300 mg powder for concentrate for solution for infusion vedolizumab
Package leaflet: Information for the patient Entyvio 300 mg powder for concentrate for solution for infusion vedolizumab This medicine is subject to additional monitoring. This will allow quick identification
More informationPrescribing Framework for Mycophenolate Mofetil for Immunosuppression in ADULTs
Hull & East Riding Prescribing Committee Prescribing Framework for Mycophenolate Mofetil for Immunosuppression in ADULTs Patient s Name:.. NHS Number: Patient s Address:... (Use addressograph sticker)
More informationIf your IBD has not been well controlled, or is flaring up quite often, tacrolimus may be added to your treatment.
If your IBD has not been well controlled, or is flaring up quite often, tacrolimus may be added to your treatment. What is tacrolimus? Patient Information Drugs for Inflammatory Bowel Disease Tacrolimus
More informationPackage leaflet: Information for the patient. Bavencio 20 mg/ml concentrate for solution for infusion avelumab
Package leaflet: Information for the patient Bavencio 20 mg/ml concentrate for solution for infusion avelumab This medicine is subject to additional monitoring. This will allow quick identification of
More informationRENFLEXIS. Treatment with RENFLEXIS. (infliximab-abda) Answers to questions you may have IMPORTANT SAFETY INFORMATION
Treatment with RENFLEXIS Answers to questions you may have You may be having conversations with your doctor about switching from your current infliximab treatment to a biosimilar medicine called RENFLEXIS.
More informationNab-Paclitaxel (Abraxane) and Gemcitabine For Pancreatic Adenocarcinoma Cumbria, Northumberland, Tyne & Wear Area Team
DRUG ADMINISTRATION SCHEDULE Day Drug Dose Route Diluent & Rate 1 8 15 Sodium Chloride 0.9% 100ml Infusion Fast Running Dexamethasone 8mg Oral Ondansetron 8mg Oral/ IV Chlorphenamine 10mg Intravenous Slow
More informationUNC INFLAMMATORY BOWEL DISEASE DRUG PROTOCOL VEDOLIZUMAB (ENTYVIO)
UNC INFLAMMATORY BOWEL DISEASE DRUG PROTOCOL VEDOLIZUMAB (ENTYVIO) TREATMENT PROTOCOL: Vedolizumab is a humanized immunoglobulin G1 monoclonal antibody that targets 41 integrin and blocks its interaction
More informationLeflunomide Treatment Rheumatology Patient Information Leaflet
Leflunomide Treatment Rheumatology Patient Information Leaflet Originator: Dr K Douglas Date: September 2011 Version: 2 Date for Review: September 2014 DGOH Ref No: DGOH/PIL/00217 Contact numbers If your
More informationUstekinumab is used to treat moderate to severe plaque psoriasis in adults. Why have I been selected for treatment with ustekinumab?
USTEKINUMAB What are the aims of this leaflet? This leaflet has been written to help you understand more about ustekinumab (Stelara TM ). It tells you what it is, how it works, how it is used to treat
More informationBreast Pathway Group Docetaxel in Advanced Breast Cancer
Breast Pathway Group Docetaxel in Advanced Breast Cancer Indication: First-line palliative treatment, with or without trastuzumab, for advanced breast cancer in patients for whom an anthracycline is not
More informationAdministration of Tuberculin Purified Protein Derivative (PPD) 2TU per 0.1ml to patients attending BCG clinics with identified TB at risk factors.
Administration of Tuberculin Purified Protein Derivative (PPD) 2TU per 0.1ml to patients attending BCG clinics with identified TB at risk factors. Special notes PPD is an unlicensed medicine and therefore
More informationUnderstanding Adalimumab
Understanding Adalimumab Turnberg Building Inflammatory Bowel Disease Service 0161 206 4023 All Rights Reserved 2018. Document for issue as handout. What is my treatment? Adalimumab is considered to be
More information1. Background: Infliximab is administered parenterally; therefore, it is not covered under retail pharmacy benefits.
Subject: Infliximab (Remicade ) Original Original Committee Approval: October 13, 2006 Revised Last Committee Approval: December 3, 2008 Last Review: October 19, 2007 1. Background: Infliximab is a genetically
More informationATEZOLIZUMAB (TECENTRIQ ) in urothelial carcinoma
DRUG ADMINISTRATION SCHEDULE Day Drug Daily Dose Route Diluent Rate Day 1 Atezolizumab 1200 mg IV Infusion 250mL 0.9% Sodium Chloride Over 60 minutes* *The initial dose of atezolizumab must be administered
More informationDERBY-BURTON CANCER NETWORK CONTROLLED DOC NO:
OBINUTUZUMAB+CHLORAMBUCIL Regimen RDH; Day 1 and 2 Dose to be given on Ward Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community
More informationPATIENT / USER INFORMATION LEAFLET. Cinryze 500 Units powder and solvent for solution for injection C1 inhibitor (human)
PATIENT / USER INFORMATION LEAFLET Cinryze 500 Units powder and solvent for solution for injection C1 inhibitor (human) Read all of this leaflet carefully before you start taking this medicine. Keep this
More informationProducts available Methotrexate tablets 2.5mg ONLY (Methotrexate tablets 10mg are NOT recommended as per NPSA guidance 5 ).
Methotrexate Traffic light classification- Amber 1 Information sheet for Primary Care Prescribers Part of the Shared Care Protocol: Management of Rheumatological Conditions with Disease-Modifying Anti
More informationHIGHLIGHTS OF PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use INFLECTRA safely and effectively. See full prescribing information for INFLECTRA. INFLECTRA (infliximab-dyyb)
More information1 of 61. WARNING: SERIOUS INFECTIONS and MALIGNANCY See full prescribing information for complete boxed warning
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use INFLECTRA safely and effectively. See full prescribing information for INFLECTRA. INFLECTRA (infliximab-dyyb)
More informationA step-by-step preparation guide
A step-by-step preparation guide This guide provides detailed instruction on the reconstitution, dilution, and storage of Veletri (epoprostenol) for Injection. It is intended to be used after your healthcare
More informationInformation on Azathioprine for Inflammatory Bowel Disease
Information on Azathioprine for Inflammatory Bowel Disease What is Azathioprine? Azathioprine belongs to a group of medicines called immunosuppressant(s). What is Azathioprine used for? Azathioprine is
More informationSHARED CARE PRESCRIBING GUIDELINE
WORKING IN PARTNERSHIP East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG, Surrey Heath CCG, North East Hampshire & Farnham CCG, Crawley CCG, Horsham & Mid-Sussex CCG SHARED
More informationPrivigen solution for infusion
Privigen solution for infusion Haematology Patient Information What is is Privigen? Privigen? Privigen belongs in a class of medicines called human normal immunoglobins. Immunoglobulins are also called
More informationOmalizumab vs. Mepolizumab for Asthma Patients: How to Decide. Indications
vs. for Asthma Patients: How to Decide Indications Asthma is indicated for patients 6 years of age and older with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity
More informationA step-by-step preparation guide
A step-by-step preparation guide For needle and needle-free systems This guide provides detailed instructions on the reconstitution, dilution, and storage of VELETRI. It is intended to be used after your
More informationINFLECTRA (infliximab-dyyb) for injection
A-APPROVED INFLECTRA (infliximab-dyyb) for injection Product information INFLECTRA NDC 0069-0809-01 Unit quantity One 20-mL vial containing 100 mg of lyophilized infliximab-dyyb Unit list price $946.28
More informationPackage leaflet: Information for the user. /.../ 50 mg powder and solvent for solution for injection/infusion. melphalan
Package leaflet: Information for the user /.../ 50 mg powder and solvent for solution for injection/infusion melphalan Read all of this leaflet carefully before you start using this medicine because it
More informationCosmoFer. Dose Selection and Calculation Guide for intravenous administration. Low molecular weight iron dextran. Revised TDI tables
CosmoFer Low molecular weight iron dextran Dose Selection and Calculation Guide for intravenous administration Revised TDI tables low Mw iron dextran Before prescribing CosmoFer please refer to full local
More informationDrug information. Secukinumab SECUKINUMAB. is used to treat psoriatic arthritis and ankylosing spondylitis. Helpline
Drug information Secukinumab SECUKINUMAB is used to treat psoriatic arthritis and ankylosing spondylitis Helpline 0800 5200 520 1 Introduction Secukinumab is a drug that can help prevent your condition
More informationHELPING YOU AND YOUR PATIENTS TALK OPENLY ABOUT MODERATELY TO SEVERELY ACTIVE RA
SIMPONI ARIA (golimumab) is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) in combination with MTX, active psoriatic arthritis, and active ankylosing
More informationWeekly methotrexate tablets
Weekly methotrexate tablets Information to read before you start treatment This information sheet has been given to you to help answer some of the questions you may have about methotrexate. It is in addition
More informationEVOGAM. Information for patients Evogam NZ Patient Brochure Update FA3
EVOGAM Information for patients 11179 Evogam NZ Patient Brochure Update FA3 Information for patients and caregivers about EVOGAM This booklet is designed to help you follow the training you will have been
More informationWhat is Enbrel? Key features
What is Enbrel? Enbrel (also known by its generic name etanercept) is a biologic medication approved in April 2004 by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe
More informationMETHOTREXATE (Adults)
Shared Care Guideline Methotrexate (Adults) Contents Introduction:... 1 Contraindications & Warnings:... 2 Interactions:... 3 Adverse Effects:... 3 Responsibilities of the specialist initiating treatment:...
More informationPRESCRIBING GUIDANCE METHOTREXATE for the treatment of vasculitis
PRESCRIBING GUIDANCE METHOTREXATE for the treatment of vasculitis For the latest information on interactions and adverse effects, always consult the latest version of the Summary of Product Characteristics
More informationPRIOR AUTHORIZATION REQUEST GUIDE
PRIOR AUTHORIZATION REQUEST GUIDE Drafting a Prior Authorization Request The following information is presented for informational purposes only and is not intended to provide reimbursement or legal advice.
More informationORENCIA (or-en-see-ah)
(or-en-see-ah) Abatacept (ab-ah-ta-sept) (rch) ; Abatacept (rch) solution for Injection (pre-filled syringe, pre-filled autoinjector) Consumer Medicine Information What is in this leaflet This leaflet
More informationHumira. (adalimumab) Drug Update Slideshow NEW INDICATION
Humira (adalimumab) NEW INDICATION Drug Update Slideshow Introduction Brand name: Humira Generic name: Adalimumab Pharmacological class: Tumor necrosis factor (TNF) blocker Strength and Formulation: 10mg/0.2mL,
More informationHorizon Scanning Technology Summary. Adalimumab (Humira) for juvenile idiopathic arthritis. National Horizon Scanning Centre.
Horizon Scanning Technology Summary National Horizon Scanning Centre Adalimumab (Humira) for juvenile idiopathic arthritis June 2007 This technology summary is based on information available at the time
More informationAtezolizumab Non-small cell lung cancer
Systemic Anti Cancer Treatment Protocol Atezolizumab Non-small cell lung cancer PROTOCOL REF: MPHAATNSCLC (Version No: 1.0) Approved for use in: Locally advanced/metastatic non squamous or squamous non-small
More information